Loading
In colorectal cancer, a KRAS blocker alone has little effect because the cell turns EGFR up; adding an EGFR antibody stops that.
This combination pairs KRAS & RAS inhibitors (the G12C inhibitors Sotorasib and Adagrasib) with an anti-EGFR antibody in Colorectal cancer. The mechanism is that colorectal epithelium has strong EGFR-driven adaptive feedback that reactivates the RAS / RAF / MEK / ERK (MAPK) pathway within hours of KRAS inhibition, so a KRAS blocker alone has little effect and adding an EGFR antibody stops the rebound. Sotorasib plus panitumumab was approved on the phase 3 CodeBreaK 300 trial, which showed a progression-free survival benefit, and adagrasib plus cetuximab was approved on KRYSTAL-1, with response rates considerably higher in combination than with monotherapy. The pairing is a stop on the KRAS roadmap from undruggable to G12C to pan-RAS.
Shares CodeBreaK 300, Adagrasib, Sotorasib, KRAS & RAS inhibitors.
Shares CodeBreaK 300, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
Shares Adagrasib, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), EGFR.
Shares CodeBreaK 300, KRAS roadmap: undruggable → G12C → pan-RAS, Sotorasib, KRAS & RAS inhibitors.
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors.
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, Colorectal cancer.
Shares Adagrasib, KRAS & RAS inhibitors.
Shares KRAS roadmap: undruggable → G12C → pan-RAS, Adagrasib, Sotorasib, KRAS & RAS inhibitors.